Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity

被引：0
|
作者：
Wood, S. [1 ]
Li, R. [1 ]
Beesley, S. [1 ]
Brown, J. [1 ]
Cominos, M. [1 ]
Hall, J. [1 ]
Sevitt, T. [1 ]
Shah, R. [1 ]
Taylor, H. [1 ]
Burcombe, R. [1 ]
机构：
[1] Maidstone Hlth Author, Oncol, Maidstone, Kent, England
来源：
LUNG CANCER | 2015年 / 87卷
关键词：
D O I：
10.1016/S0169-5002(15)50065-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
66
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [1] Is Advanced Age a Prognostic Factor for Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer (NSCLC)?
    Batum, O.
    Anar, C.
    Ozdogan, Y.
    Ermin, S.
    Yilmaz, U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer (NSCLC)
    Fruh, M.
    Tribodet, H.
    Pignon, J.
    Winton, T.
    Le Chevalier, T.
    Scagliotti, G. V.
    Douillard, J. Y.
    Seymour, L.
    Spiro, S. G.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
    Lakkunarajah, Suganija
    Breadner, Daniel A.
    Zhang, Hanbo
    Yamanaka, Ellen
    Warner, Andrew
    Welch, Stephen
    CURRENT ONCOLOGY, 2021, 28 (05) : 4031 - 4041
  • [4] WHY IS ADJUVANT CHEMOTHERAPY IN COMPLETELY-RESECTED NON SMALL CELL LUNG CANCER (NSCLC) NOT ADMINISTERED? A PROSPECTIVE ANALYSIS
    El Sheshtawy, W.
    Ngadi, I.
    Zaidi, S.
    Mulder, D.
    Sirois, C.
    Ofiara, L.
    Gruber, J.
    Faria, S.
    Hirsh, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 113 - 113
  • [5] Long-Term Results of Adjuvant Chemotherapy in Completely Resected NSCLC Patients
    Wurstbauer, Karl
    Sedlmayer, Felix
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (07) : 404 - 405
  • [6] Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)
    Liang, Ying
    Wakelee, Heather A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (05) : 403 - 410
  • [7] A Retrospective Analysis of Adjuvant Chemotherapy in Patients with Completely Resected SCLC
    Tamura, Yosuke
    Fujisaka, Yasuhito
    Nakamura, Takahito
    Tsuji, Hiroyuki
    Matsunaga, Ninso
    Kawaguchi, Tetsufumi
    Imanishi, Masashi
    Yoshida, Syuhei
    Miyoshi, Keiji
    Ikeda, Soichiro
    Goto, Isao
    Hanafusa, Toshiaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S744 - S744
  • [8] Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
    Katsurada, N.
    Tachihara, M.
    Hatakeyama, Y.
    Koyama, K.
    Yumura, M.
    Kiriu, T.
    Dokuni, R.
    Hazama, D.
    Tokunaga, S.
    Tamura, D.
    Nakata, K.
    Yamamoto, M.
    Kamiryo, H.
    Kobayashi, K.
    Tanaka, Y.
    Maniwa, Y.
    Nishimura, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S885 - S885
  • [9] Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC
    Yu, Hongliang
    Gu, Dayong
    Qian, Pudong
    PLOS ONE, 2020, 15 (12):
  • [10] Survival data of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected NSCLC
    Kenmotsu, Hirotsugu
    Ohde, Yasuhisa
    Wakuda, Kazushige
    Nakashima, Kazuhisa
    Omori, Shota
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    ANNALS OF ONCOLOGY, 2017, 28
12345